Compare CRNX & USAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRNX | USAC |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Natural Gas Distribution |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | 2018 | 2011 |
| Metric | CRNX | USAC |
|---|---|---|
| Price | $42.21 | $26.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | ★ $76.75 | $26.67 |
| AVG Volume (30 Days) | ★ 1.3M | 287.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 7.72% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,039,000.00 | ★ $698,365,000.00 |
| Revenue This Year | $720.10 | $33.35 |
| Revenue Next Year | $184.67 | $6.09 |
| P/E Ratio | ★ N/A | $31.25 |
| Revenue Growth | N/A | ★ 19.51 |
| 52 Week Low | $25.83 | $21.85 |
| 52 Week High | $57.99 | $30.55 |
| Indicator | CRNX | USAC |
|---|---|---|
| Relative Strength Index (RSI) | 71.81 | 46.70 |
| Support Level | $38.68 | $26.11 |
| Resistance Level | $44.89 | $28.79 |
| Average True Range (ATR) | 1.71 | 0.94 |
| MACD | 0.74 | 0.06 |
| Stochastic Oscillator | 97.89 | 48.90 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
USA Compression Partners LP provides compression services in the United States in terms of total compression fleet horsepower to customers relating to infrastructure applications, including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. It engineers, designs, operates, services, and repairs its compression units and maintains related support inventory and equipment. The company provides compression services throughout the U.S., including the Utica, Marcellus, Permian, Denver-Julesburg, Eagle Ford, Mississippi Lime, Granite Wash, Woodford, Barnett, and Haynesville.